Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants : Comparison with Warfarin

Kawabori, Masahito; Niiya, Yoshimasa; Iwasaki, Motoyuki; Mabuchi, Shoji; Ozaki, Hiroyuki; Matsubara, Koji; Houkin, Kiyohiro

Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants : Comparison with Warfarin

Kawabori, Masahito; Niiya, Yoshimasa; Iwasaki, Motoyuki et al.

Journal of stroke & cerebrovascular diseases, 2018, 27(5), 1338-1342

Permalink : https://hdl.handle.net/2115/73805

このアイテムのアクセス数:768件（2026-08-08 01:14 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
JStrokeCerebrovascDis27_1338	pdf	304 KB	774

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/73805
タイトル	Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants : Comparison with Warfarin
その他のタイトル	Characteristics of ICH with Warfarin and DOAC
著者	Kawabori, Masahito ; Niiya, Yoshimasa ; Iwasaki, Motoyuki ; Mabuchi, Shoji ; Ozaki, Hiroyuki ; Matsubara, Koji ; Houkin, Kiyohiro
e-Rad_Researcher 50399870 著者名 Kawabori, Masahito
著者名 Niiya, Yoshimasa
著者名 Iwasaki, Motoyuki
著者名 Mabuchi, Shoji
著者名 Ozaki, Hiroyuki
著者名 Matsubara, Koji
e-Rad_Researcher 90229146 著者名 Houkin, Kiyohiro
言語	英語
キーワード	DOAC
	intracerebral hemorrhage
	warfarin
	stroke
発行日	2018-05
出版者	Elsevier
収録物名	Journal of stroke & cerebrovascular diseases
巻(号)	27(5)
ページ	1338-1342
抄録	Background: Direct oral coagulants (DOAC) have been shown to decrease the frequency of intracerebral hemorrhage (ICH) compared with warfarin. However, the precise characteristics, such as the size and locations of the hemorrhage, and outcome and onset time of ICH in patient taking DOAC are not fully elucidated. Methods: We retrospectively analyzed the characteristics of symptomatic patients with ICH taking either DOAC or warfarin between January 2012 and December 2015. Results: Out of 400 consecutive patients with ICH, 15 patients were DOAC-ICH and 24 patients were warfarin-ICH. DOAC-ICH was observed in 6 patients with 10 mg of rivaroxaban, 5 patients with 15 mg of rivaroxaban, and 1 patient with 10 mg of apixaban, 5 mg of apixaban, 30 mg of edoxaban, and 60 mg of edoxaban. Prothrombin time was well controlled in most of the warfarin-ICH patients (83.3%). The locations of ICH were similar in both groups; however, median ICH volume was significantly smaller in DOAC-ICH patients than in warfarin-ICH patients (P<.01) and ICH around basal ganglia seemed to show great difference between the groups. DOAC-ICH patients showed better neurological outcome at the time of discharge than warfarin patients (P<.01), and the ratio of good prognosis was significantly higher in the DOAC-ICH patients than in the warfarin-ICH patients (P<.01). The onset of warfarin-ICH was frequently observed in the morning and evening, whereas DOAC-ICH did not show any specific onset time. Conclusions: Patients with DOAC-ICH showed smaller ICH volume and better clinical outcomes than patients with warfarin-ICH, and DOAC-ICH did not show any specific onset peak.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
権利情報	© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN	1052-3057
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.12.020